Skip to main content
Top
Published in: BMC Infectious Diseases 1/2015

Open Access 01-12-2015 | Research article

Assessment of Directly Observed Therapy (DOT) following tuberculosis regimen change in Addis Ababa, Ethiopia: a qualitative study

Authors: Daniel Fiseha, Meaza Demissie

Published in: BMC Infectious Diseases | Issue 1/2015

Login to get access

Abstract

Background

Tuberculosis remains a major public health problem in Ethiopia. In 2010 the TB treatment regimen was shortened from 8 to 6-months treatment. With this new regimen, the full course of treatment should be taken under Directly Observed Therapy (DOT) unlike the 8-month regimen where TB patients were only observed during the intensive phase, this has not been tried before and may be difficult to implement. Therefore this study aimed to investigate the experiences from both TB patients and health care providers’ perspective of implementing DOT for the full course of TB treatment.

Methods

Qualitative study consisted of 11 in-depth interviews and 4 Focus Group Discussions (FDGs) were conducted between March and April, 2014. Overall, 18 TB patients and 16 HCPs were involved from three selected public health facilities (2 Health Centers and 1 Hospital) in Addis Ababa, Ethiopia. Qualitative data analysis software (Open Code Version 3.5) was employed to identify the key issues from these interviews through coding, categorization and grouping into emergent themes.

Results

Participants reported that making a daily visit to health facilities for DOT was difficult due to the distance of the facilities from their residences, lack of or high transportation cost and had undesired implications on their work and social lives. TB patients had to overcome many challenges to comply with TB treatment on a daily basis. HCPs also indicated the difficulties of implementing facility based daily DOT mainly due the implication it had on their TB patients and stated DOT had not always been implemented for the full course as recommended. HCPs also shared deep concern regarding the risk of acquiring multiple drug resistant TB.

Conclusion

This study indicated there are several challenges associated with facility based daily DOT as a method of TB treatment supervision in public health facilities in Addis Ababa. This may be indicative of the situation in other health facilities in Addis Ababa as well as elsewhere in the country. Hence the TB control program has to explore how best to improve TB treatment delivery options to ensure adequate treatment. A more patient-centered approach could be strengthened by further decentralizing the DOT to the community level in order to ensure adherence of patients to their TB treatment.
Literature
1.
go back to reference World Health Organization: Global Tuberculosis control report 2012. Geneva, Switzerland: WHO; 2013. p. 9–26. World Health Organization: Global Tuberculosis control report 2012. Geneva, Switzerland: WHO; 2013. p. 9–26.
2.
go back to reference World Health Organization. The global plan to stop TB 2011–2015: transforming the fight towards elimination of tuberculosis. Geneva, Switzerland: WHO; 2010. p. 10–5. World Health Organization. The global plan to stop TB 2011–2015: transforming the fight towards elimination of tuberculosis. Geneva, Switzerland: WHO; 2010. p. 10–5.
3.
go back to reference Federal Democratic Republic of Ethiopian Ministry of health: Health and Health related inidicators: Addis Ababa, Ethiopia, 2011/12. P.33-36. Federal Democratic Republic of Ethiopian Ministry of health: Health and Health related inidicators: Addis Ababa, Ethiopia, 2011/12. P.33-36.
4.
go back to reference Federal Ministry of Health Ethiopia. Guidelines for clinical and programmatic management of TB, leprosy and TB/HIV in Ethiopia, 5th edition, Addis Ababa, Ethiopia, March 2013. P. 1–25. Federal Ministry of Health Ethiopia. Guidelines for clinical and programmatic management of TB, leprosy and TB/HIV in Ethiopia, 5th edition, Addis Ababa, Ethiopia, March 2013. P. 1–25.
5.
go back to reference World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva, Switzerland: WHO; 2003. p. 33–103. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva, Switzerland: WHO; 2003. p. 33–103.
6.
go back to reference World Health Organization. Treatment of tuberculosis guidelines. 4th ed. Geneva, Switzerland: WHO; 2009. p. 47–8. World Health Organization. Treatment of tuberculosis guidelines. 4th ed. Geneva, Switzerland: WHO; 2009. p. 47–8.
7.
go back to reference Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomized trial. Lancet. 2004;364:1244–51.CrossRefPubMed Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomized trial. Lancet. 2004;364:1244–51.CrossRefPubMed
8.
go back to reference Dick M, Andrea B, Anita P, Ian M, Sarah R, Madhukar P, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 2009;6:e1000146.CrossRef Dick M, Andrea B, Anita P, Ian M, Sarah R, Madhukar P, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 2009;6:e1000146.CrossRef
9.
go back to reference Wells WA, Konduri N, Chen C, Lee D, Ignatius HR, Gardiner E, et al. Tuberculosis regimen change in high-burden countries. Int J Tuberc Lung Dis. 2010;14(12):1538–47.PubMed Wells WA, Konduri N, Chen C, Lee D, Ignatius HR, Gardiner E, et al. Tuberculosis regimen change in high-burden countries. Int J Tuberc Lung Dis. 2010;14(12):1538–47.PubMed
10.
go back to reference Federal Ministry of Health Ethiopia. Interim Guideline for Shifting from EH to RH Regimen. Addis Ababa, Ethiopia, December, 2010. p 4–27. Federal Ministry of Health Ethiopia. Interim Guideline for Shifting from EH to RH Regimen. Addis Ababa, Ethiopia, December, 2010. p 4–27.
11.
go back to reference World Health Organization. The stop TB strategy: building on and enhancing DOTS to meet the TB-related millennium development goals. Geneva, Switzerland: WHO; 2006. 19–591. World Health Organization. The stop TB strategy: building on and enhancing DOTS to meet the TB-related millennium development goals. Geneva, Switzerland: WHO; 2006. 19–591.
12.
go back to reference Federal Ministry of Health. Ethiopia Demographic and Health Survey (EDHS). Addis Ababa, Ethiopia, 2011 p. 33–36. Federal Ministry of Health. Ethiopia Demographic and Health Survey (EDHS). Addis Ababa, Ethiopia, 2011 p. 33–36.
13.
go back to reference World Health Organization. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: WHO; 2003. 33–37. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: WHO; 2003. 33–37.
14.
go back to reference Paul G, Helen S, Salla M, Jimmy V. Promoting adherence to tuberculosis treatment. Bull World Health Organ. 2007;85(5):404–6.CrossRef Paul G, Helen S, Salla M, Jimmy V. Promoting adherence to tuberculosis treatment. Bull World Health Organ. 2007;85(5):404–6.CrossRef
15.
go back to reference Mette S, Frich JC, Gunnar B. Barriers and enablers in the management of tuberculosis treatment in Addis Ababa, Ethiopia: a qualitative study. BMC Public Health. 2008;8:11.CrossRef Mette S, Frich JC, Gunnar B. Barriers and enablers in the management of tuberculosis treatment in Addis Ababa, Ethiopia: a qualitative study. BMC Public Health. 2008;8:11.CrossRef
16.
go back to reference Gebremariam MK, Bjune GA, Frich JC. Barriers and facilitators of adherence to TB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;10:651.CrossRefPubMedPubMedCentral Gebremariam MK, Bjune GA, Frich JC. Barriers and facilitators of adherence to TB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;10:651.CrossRefPubMedPubMedCentral
17.
go back to reference Takele T, Meaza D, Yemane B, Yigzaw K, Markos A. Long distance travelling and financial burdens discourage tuberculosis DOTs treatment initiation and compliance in Ethiopia: a qualitative study. BMC Public Health. 2013;13:424.CrossRef Takele T, Meaza D, Yemane B, Yigzaw K, Markos A. Long distance travelling and financial burdens discourage tuberculosis DOTs treatment initiation and compliance in Ethiopia: a qualitative study. BMC Public Health. 2013;13:424.CrossRef
18.
go back to reference Datiko DG, Bernt L. Health extension workers improve tuberculosis case detection and treatment success in southern Ethiopia: a community randomized trial. PLoS One. 2009;5:e5443.CrossRef Datiko DG, Bernt L. Health extension workers improve tuberculosis case detection and treatment success in southern Ethiopia: a community randomized trial. PLoS One. 2009;5:e5443.CrossRef
19.
go back to reference Akramul Islam MD, Susumu W, Nobukatsu I, Chowdhury AMR, Patrick Vaughan J. Cost-effectiveness of community health workers in tuberculosis control in Bangladesh. Bull World Health Organ. 2002;80(6):6–6. Akramul Islam MD, Susumu W, Nobukatsu I, Chowdhury AMR, Patrick Vaughan J. Cost-effectiveness of community health workers in tuberculosis control in Bangladesh. Bull World Health Organ. 2002;80(6):6–6.
Metadata
Title
Assessment of Directly Observed Therapy (DOT) following tuberculosis regimen change in Addis Ababa, Ethiopia: a qualitative study
Authors
Daniel Fiseha
Meaza Demissie
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2015
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-015-1142-2

Other articles of this Issue 1/2015

BMC Infectious Diseases 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine